2/2 The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
2/2 The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
批准号:
10214200
负责人:
Sarah J Ratcliffe
金额:
$54.44万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-03 至 2026-11-30
关键词:
AddressAlveolarBiometryBronchopulmonary DysplasiaCase Report FormChest wall structureChildhoodChronic lung diseaseClinical TrialsCollaborationsContinuous Positive Airway PressureCost SavingsDataData Coordinating CenterData SecurityDevelopmentDocumentationEnsureExposure toFAIR principlesFDA approvedFailureFamiliarityFundingGestational AgeGoalsHealth Care CostsHourHumanIncidenceInfantInjuryIntermittent Positive-Pressure VentilationLungMechanical ventilationMeta-AnalysisMethodologyMethodsMorbidity - disease rateMulti-Institutional Clinical TrialNoseOutcomeOxygenPhasePhase III Clinical TrialsPhysiologicalPositioning AttributePregnancyPremature BirthPremature InfantQuality ControlRandomized Controlled TrialsReproducibility of ResultsResearchResearch DesignRespiratory DiaphragmRespiratory FailureSecurityStatistical Data InterpretationTechnologyTestingTidal VolumeUnited StatesUnited States National Institutes of HealthVentilator-induced lung injuryclinical research siteclinically relevantdata infrastructuredata managementdata sharingdata structureevidence baseimprovedneurotransmissionnoveloperationpatient populationprematurepressurepreventquality assurancerandomized trialrecruitrelating to nervous systemrespiratoryventilationyears of life lost
中文摘要
点击翻译按钮获取中文摘要
英文摘要
SUMMARY
Chronic lung disease and complications from preterm birth are the leading pediatric contributors to years of life
lost in the USA. Bronchopulmonary dysplasia (BPD), a chronic lung disease, is the most common sequela of
prematurity and is the leading respiratory cause of childhood morbidity. In the United States alone BPD
accounts for over $2.4 billion in healthcare costs annually. Ventilator induced lung injury (VILI) is an accepted
and important contributor to BPD. Exposure to oxygen and positive pressure ventilation leads to developmental
arrest and parenchymal injury in the immature preterm lung. Lung protective strategies therefore prioritize non-
invasive respiratory support for preterm infants with respiratory failure, but failure rates of non-invasive
respiratory support (ie: continuous positive airway pressure [CPAP]) are high. In meta-analysis of trials of nasal
non-invasive intermittent positive pressure ventilation (NIPPV), synchronized NIPPV significantly reduced the
incidence of BPD when compared with CPAP. This benefit was not seen with non-synchronized NIPPV.
However, current standard means of synchronization are unreliable and do not deliver consistent
synchronization. Neurally Adjusted Ventilatory Assist (NAVA), an FDA approved technology, is a novel method
to synchronize non-invasive support (NIV) with infant respiratory drive. This effective non-invasive
synchronization matches electrical diaphragmatic activity to deliver synchronized and accurate tidal volumes in
proportion to the neural signal. In these clustered UG3/UH3 and U24 applications, we propose a pragmatic,
unblinded, Phase III, randomized controlled trial (RCT) in 358 preterm infants 240/7-276/7 weeks gestation in
respiratory failure to determine if NIV-NAVA, compared with non-synchronized nasal intermittent positive
pressure ventilation (NIPPV), will reduce the incidence of extubation failure within 5 days of extubation from
mechanical ventilation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
2/2 The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
-
批准号:10479806
-
项目类别:
-
资助金额:$42.63万
-
财政年份:2021
-
负责人:Sarah J Ratcliffe
-
依托单位:
海外基金